Our commitment to quality: batch by batch
Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.
A selection of other videos
Compiled from the various subject areas.
Press Releases
Please find the latest press releases from Avextra here.
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…
Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie
Auf dem virtuellen Deutschen Schmerz und Palliativtag im März haben Avextra und die Deutsche Gesellschaft für Schmerzmedizin (DGS) in einem Symposium ihre Pläne für eine gemeinsame prospektive, nicht-interventionelle, 12-wöchige Parallelgruppenstudie…
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…
Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.
Heute ist ein historischer Tag in Deutschland, an dem große Fortschritte bei der Entstigmatisierung der Cannabispflanze gemacht wurden. Martha Lurther, CSO bei Avextra, teilt ihre Gedanken zu den deutschen Plänen.…
Avextra AG Announces Closing of EU 17 Million Capital Raise
Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…
Avextra erweitert Cannabis-Portfolio um neue Dronabinol-Lösung
Bensheim, 13. Februar 2023 – Apotheken können ab sofort Dronabinol – in Form einer öligen Zubereitung – über Avextra beziehen. Die Dronabinol-Lösung vereinfacht und beschleunigt die Herstellung der Rezepturherstellung. Das…
Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom
BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful…
Medical Device Submission for a Cannabis Extract Inhaler
Avextra has commissioned the Leading Medical Device Specialists Activoris and Actarmo to prepare the EU Medical Device Submission for a Cannabis Extract Inhaler Together these three partners will develop a…
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…
Germany unveils scaled-down recreational cannabis legalization plan
Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…
Avextra AG Announces Closing of EU 17 Million Capital Raise
Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…
Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom
BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful…
Medical Device Submission for a Cannabis Extract Inhaler
Avextra has commissioned the Leading Medical Device Specialists Activoris and Actarmo to prepare the EU Medical Device Submission for a Cannabis Extract Inhaler Together these three partners will develop a…
Eurox has rebranded as Avextra
Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich…
New board member at Eurox AG: Marla Luther is Chief Strategy Officer
Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra name. Full article
PRESS CONTaCT
